Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$62.14
-1.57%
Alpha Vantage · 11/6/2026
Adjusted daily closes · 252 observations · as of Nov 6, 2026
1 month
+4.3%
3 months
-3.2%
6 months
+13.0%
1 year
+39.1%
Year to date
+20.3%
52-week range
$43.85 – $67.40
Latest reported period: Sep 30, 2026
Market cap
$127.02B
P/E
13.7
P/B
5.4
P/S
2.5
Revenue
$50.03B
Net income
$9.24B
Diluted EPS
4.51
Gross margin
69.20%
Net margin
18.50%
Return on equity
43.90%
Total debt
$42.88B
Cash
$9.57B
Free cash flow
$9.29B
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Sep 30, 2026 | $13.07B | $2.16B | 68.30% | 16.50% | $3.84B |
| Jun 30, 2026 | $12.97B | $3.32B | 71.30% | 25.60% | $3.09B |
| Mar 31, 2026 | $11.49B | $2.68B | 70.20% | 23.30% | $757M |
| Dec 31, 2025 | $12.5B | $1.09B | 67.20% | 8.70% | $1.6B |
| Sep 30, 2025 | $12.22B | $2.2B | 71.90% | 18.00% | $5.99B |
| Jun 30, 2025 | $12.27B | $1.31B | 72.50% | 10.70% | $3.56B |
| Mar 31, 2025 | $11.2B | $2.46B | 72.90% | 21.90% | $1.69B |
| Dec 31, 2024 | $12.34B | $72M | 61.00% | 0.60% | $4.06B |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Julia A. Haller has filed a Form 144 with the SEC for the proposed sale of 3,800 shares of Bristol Myers Squibb Co. common stock. The aggregate market value of these securities is $250,000, with an approximate sale date of November 5, 2026, on the NYSE. The filing details the acquisition of these shares through stock bonuses from Bristol-Myers Squibb in 2021 and 2022.
Original sourceMirae Asset Global Investments Co. Ltd. has purchased 61,385 shares of Expand Energy Corporation (NASDAQ:EXE) worth approximately $5.16 million in the third quarter, establishing a new position. Expand Energy reported strong quarterly earnings, beating analyst expectations with EPS of $1.46 and revenue of $3.29 billion, and also declared a quarterly dividend of $0.575 per share. Analysts currently have a "Moderate Buy" consensus rating for the stock with an average price target of $123.
Original sourceXencor, Inc. reported its financial results for the third quarter ended September 30, 2026, highlighting progress across its clinical-stage pipeline for cancer and autoimmune diseases. Key updates include compelling clinical data for XmAb819 in advanced clear cell renal cell carcinoma, upcoming presentations for plamotamab in rheumatoid arthritis, and on-track development for TL1A-targeting programs XmAb942 and XmAb412. The company also detailed significant milestones achieved with partners Amgen, Astellas, and Zenas BioPharma, and reported a net income of $39.4 million for the quarter.
Original source